Cardiovascular Autonomic Neuropathy and Distal Symmetric Sensorimotor Polyneuropathy: These Two Diabetic Microvascular Complications do not Invariably Co-Exist

Author(s): Kalliopi Pafili*, Grigoris Trypsianis, Dimitrios Papazoglou, Efstratios Maltezos, Nikolaos Papanas.

Journal Name: Current Vascular Pharmacology

Volume 18 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Cardiovascular autonomic neuropathy (CAN) and distal symmetrical sensorimotor polyneuropathy (DSPN) are serious microvascular complications of diabetes mellitus (DM). Their simultaneous development remains disputable. The aim of the present study was to examine the correlation between CAN and the presence/severity of DSPN in DM.

Methods: Subjects with type 1 (group A: n=51; mean age 40.4 years) and type 2 DM (group B: n=153; mean age 64.6 years) were studied. Evaluation of DSPN was based on neuropathy disability score. Assessment of CAN was based on the battery of 4 standardized cardiovascular autonomic function tests.

Results: In group A, patients with moderate/severe DSPN exhibited a 12-fold higher likelihood of CAN in univariate analysis (p=0.035). However, significance was lost after adjustment for gender, age, DM duration, and haemoglobin A1c. In group A, likelihood for CAN did not correlate with the presence of mild DSPN in univariate and multivariate analysis. In group B, likelihood of CAN was similar in patients with mild and in those with moderate/severe DSPN compared with patients without DSPN in univariate and multivariate analysis. In between group comparison CAN was similarly distributed in the 2 groups (p for interaction=0.367), in patients with no, mild and moderate/severe DSPN.

Conclusion: CAN does not always co-exist with degrees of DSPN, ranging from mild to moderate/ severe and is similarly distributed in T1DM and T2DM patients with mild and moderate/severe DSPN and in patients without DSPN.

Keywords: Autonomic neuropathy, diabetes mellitus, microvascular complications, peripheral neuropathy, somatic neuropathy, CAN.

[1]
Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007; 115: 387-97.
[2]
Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: A meta-analysis. Diabetes Care 2003; 26: 1895-901.
[3]
Verrotti A, Prezioso G, Scattoni R, Chiarelli F. Autonomic neuropathy in diabetes mellitus. Front Endocrinol 2014; 5: 205.
[4]
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
[5]
Zoppini G, Cacciatori V, Raimondo D, et al. Prevalence of cardiovascular autonomic neuropathy in a cohort of patients with newly diagnosed type 2 diabetes: The Verona newly diagnosed type 2 diabetes study (VNDS). Diabetes Care 2015; 38: 1487-93.
[6]
Low PA, Benrud-Larson LM, Sletten DM, et al. Autonomic symptoms and diabetic neuropathy: A population-based study. Diabetes Care 2004; 27: 2942-7.
[7]
Kennedy WR, Navarro X, Goetz FC, Sutherland DE, Najarian JS. Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med 1990; 322: 1031-7.
[8]
Kempler P, Tesfaye S, Chaturvedi N, et al. Autonomic neuropathy is associated with increased cardiovascular risk factors: The Eurdiab IDDM complications study. Diabet Med 2002; 19: 900-9.
[9]
Ko SH, Park SA, Cho JH, et al. Progression of cardiovascular autonomic dysfunction in patients with type 2 diabetes: A 7-year follow-up study. Diabetes Care 2008; 31: 1832-6.
[10]
Dimitropoulos G, Tahrani AA, Stevens MJ. Cardiac autonomic neuropathy in patients with diabetes mellitus. World J Diabetes 2014; 5: 17-39.
[11]
Papanas N, Pafili K, Maltezos E. Charcot osteoarthropathy and coronary artery disease in diabetes: The twilight of innocence? Acta Diabetol 2016; 53: 123-4.
[12]
Papanas N, Ziegler D. Risk factors and comorbidities in diabetic neuropathy: An update 2015. Rev Diabet Stud 2015; 12: 48-62.
[13]
Pafili K, Papanas N, Ziegler D. Neuropathy in diabetes: One cannot begin it too soon. Angiology 2018; 69(9): 752-4.
[14]
Young RJ, Zhou YQ, Rodriguez E, Prescott RJ, Ewing DJ, Clarke BF. Variable relationship between peripheral somatic and autonomic neuropathy in patients with different syndromes of diabetic polyneuropathy. Diabetes 1986; 35: 192-7.
[15]
Ewing DJ, Clarke BF. Diagnosis and management of diabetic autonomic neuropathy. Br Med J (Clin Res Ed) 1982; 285: 916-8.
[16]
Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: A position statement by the American Diabetes Association. Diabetes Care 2017; 40: 136-54.
[17]
Spallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic neuropathy in diabetes: Clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev 2011; 27: 639-53.
[18]
Smith SA. Reduced sinus arrhythmia in diabetic autonomic neuropathy: Diagnostic value of an age-related normal range. Br Med J (Clin Res Ed) 1982; 285: 1599-601.
[19]
Stranieri A, Abawajy J, Kelarev A, Huda S, Chowdhury M, Jelinek HF. An approach for Ewing test selection to support the clinical assessment of cardiac autonomic neuropathy. Artif Intell Med 2013; 58: 185-93.
[20]
Liatis S, Marinou K, Tentolouris N, Pagoni S, Katsilambros N. Usefulness of a new indicator test for the diagnosis of peripheral and autonomic neuropathy in patients with diabetes mellitus. Diabet Med 2007; 24: 1375-80.
[21]
Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36: 150-4.
[22]
Papanas N, Paschos P, Papazoglou D, et al. Accuracy of the neuropad test for the diagnosis of distal symmetric polyneuropathy in type 2 diabetes. Diabetes Care 2011; 34: 1378-82.
[23]
Lluch I, Hernández A, Real JT, et al. Cardiovascular autonomic neuropathy in type 1 diabetic patients with and without peripheral neuropathy. Diabetes Res Clin Pract 1998; 42: 35-40.
[24]
Piaggesi A, Castro Lòpez E, Bini L, et al. Measurable deficit of autonomic and sensory nerve function in asymptomatic diabetic patients. J Diabetes Complications 1992; 6: 157-62.
[25]
Pappachan JM, Sebastian J, Bino BC, et al. Cardiac autonomic neuropathy in diabetes mellitus: Prevalence, risk factors and utility of corrected QT interval in the ECG for its diagnosis. Postgrad Med J 2008; 84: 205-10.
[26]
Voulgari C, Psallas M, Kokkinos A, Argiana V, Katsilambros N, Tentolouris N. The association between cardiac autonomic neuropathy with metabolic and other factors in subjects with type 1 and type 2 diabetes. J Diabetes Complications 2011; 25: 159-67.
[27]
Moţăţăianu A, Bălaşa R, Voidăzan S, Bajkó Z. Cardiovascular autonomic neuropathy in context of other complications of type 2 diabetes mellitus. BioMed Res Int 2013; 2013507216
[28]
Töyry JP, Partanen JV, Niskanen LK, Länsimies EA, Uusitupa MI. Divergent development of autonomic and peripheral somatic neuropathies in NIDDM. Diabetologia 1997; 40(8): 953-8.
[29]
Fleischer J, Yderstraede K, Gulichsen E, et al. Cardiovascular autonomic neuropathy is associated with macrovascular risk factors in type 2 diabetes: New technology used for routine large-scale screening adds new insight. J Diabetes Sci Technol 2014; 8: 874-80.
[30]
Tentolouris N, Pagoni S, Tzonou A, Katsilambros N. Peripheral neuropathy does not invariably coexist with autonomic neuropathy in diabetes mellitus. Eur J Intern Med 2001; 12: 20-7.
[31]
Lange-Maia BS, Newman AB, Jakicic JM, et al. Relationship between sensorimotor peripheral nerve function and indicators of cardiovascular autonomic function in older adults from the health, aging and body composition study. Exp Gerontol 2017; 96: 38-45.
[32]
Jin HY, Park TS. Can nerve conduction studies detect earlier and predict clinical diabetic neuropathy? J Diabetes Investig 2015; 6: 18-20.
[33]
Körei AE, Istenes I, Papanas N, Kempler P. Small-fiber neuropathy: a diabetic microvascular complication of special clinical, diagnostic, and prognostic importance. Angiology 2016; 67: 49-57.
[34]
Valensi P, Huard JP, Giroux C, Attali JR. Factors involved in cardiac autonomic neuropathy in diabetic patients. J Diabetes Complications 1997; 11(3): 180-7.
[35]
Pop-Busui R, Kirkwood I, Schmid H, et al. Sympathetic dysfunction in type 1 diabetes: Association with impaired myocardial blood flow reserve and diastolic dysfunction. J Am Coll Cardiol 2004; 44: 2368-74.
[36]
Bissinger A. Cardiac autonomic neuropathy: Why should cardiologists care about that? J Diabetes Res 2017; 20175374176
[37]
Kissel JT, Smith AG. Understanding small fiber neuropathy: the long and short of it. JAMA Neurol 2016; 73: 635-7.
[38]
Elliott J, Tesfaye S, Chaturvedi N, et al. Large-fiber dysfunction in diabetic peripheral neuropathy is predicted by cardiovascular risk factors. Diabetes Care 2009; 2: 1896-900.
[39]
Pafili K, Papanas N, Maltezos E. Treatment of diabetic complications: How can we learn by seeking and blundering? Angiology 2015; 66: 301-3.
[40]
Pafili K, Maltezos E, Papanas N. NC-stat for the diagnosis of diabetic polyneuropathy. Expert Rev Med Devices 2017; 14: 251-4.
[41]
Papanas N, Boulton AJ, Malik RA, et al. A simple new non-invasive sweat indicator test for the diagnosis of diabetic neuropathy. Diabet Med 2013; 30: 525-34.
[42]
Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-25.
[43]
Obrosova IG, Julius UA. Role for poly(ADP-ribose) polymerase activation in diabetic nephropathy, neuropathy and retinopathy. Curr Vasc Pharmacol 2005; 3: 267-83.
[44]
Obrosova IG, Xu W, Lyzogubov VV, et al. PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy. Free Radic Biol Med 2008; 44: 972-81.
[45]
Hotta N, Akanuma Y, Kawamori R, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: The 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial. Diabetes Care 2006; 29: 1538-44.
[46]
Ikeda T, Iwata K, Tanaka Y. Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 1999; 43: 193-8.
[47]
Körei AE, Kempler M, Istenes I, et al. Why not to use the handgrip test in the assessment of cardiovascular autonomic neuropathy among patients with diabetes mellitus? Curr Vasc Pharmacol 2017; 15: 66-73.
[48]
Pafili K, Maltezos E, Papanas N. Editorial: Limited utility of the handgrip test for the diagnosis of diabetic cardiovascular autonomic neuropathy: There’s time enough, but none to spare. Curr Vasc Pharmacol 2017; 15: 74-6.
[49]
Vinik AI, Maser RE, Ziegler D. Neuropathy: The crystal ball for cardiovascular disease? Diabetes Care 2010; 33: 1688-90.
[50]
Calles-Escandón J, Lovato LC, Simons-Morton DG, et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: The action to control cardiovascular risk in diabetes (ACCORD) trial. Diabetes Care 2010; 33: 721-7.
[51]
Papanas N, Maltezos E. Etiology, pathophysiology and classifications of the diabetic Charcot foot. Diabet Foot Ankle 2013; 4.
[52]
Bergis D, Bergis PM, Hermanns N, Zink K, Haak T. Coronary artery disease as an independent predictor of survival in patients with type 2 diabetes and Charcot neuro-osteoarthropathy. Acta Diabetol 2014; 51: 1041-8.
[53]
Wukich DK, Raspovic KM, Suder NC. Prevalence of peripheral arterial disease in patients with diabetic Charcot neuroarthropathy. J Foot Ankle Surg 2016; 55: 727-31.
[54]
Vas PRJ, Alberti KG, Edmonds ME. Prediabetes: Moving away from a glucocentric definition. Lancet Diabetes Endocrinol 2017; 5: 848-9.
[55]
Rabinowe SL, Brown FM, Watts M, Smith AM. Complement-fixing antibodies to sympathetic and parasympathetic tissues in IDDM. Autonomic brake index and heart-rate variation. Diabetes Care 1990; 13: 1084-8.
[56]
Zanone MM, Raviolo A, Coppo E, et al. Association of autoimmunity to autonomic nervous structures with nerve function in patients with type 1 diabetes: A 16-year prospective study. Diabetes Care 2014; 37: 1108-15.
[57]
Berntorp K, Frid A, Alm R, Fredrikson GN, Sjöberg K, Ohlsson B. Antibodies against gonadotropin-releasing hormone (GnRH) in patients with diabetes mellitus is associated with lower body weight and autonomic neuropathy. BMC Res Notes 2013; 6: 329.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 1
Year: 2020
Page: [50 - 56]
Pages: 7
DOI: 10.2174/1570161116666180829120101
Price: $65

Article Metrics

PDF: 15
HTML: 2